Connect with us

Psychedelics

VANCOUVER COMPANY SAYS IT HAS CREATED THE WORLD’S FIRST EVER AYAHUASCA PILL

Published

on


It looks like a pill, and it tastes just like one…but this isn’t your typical over-the-counter medication. Leading the charge in natural drug development, Vancouver-basedFilament Healthis pioneering a breakthrough medical-grade ayahuasca pill.

This novel concept could potentially help individuals access an authentic ayahuasca experience without disrupting their daily lives or requiring a trip to South America.

The Company is on the brink of obtaining FDA authorization to initiate its pioneering Phase 1 clinical trial for its ayahuasca pill, with expectations that it will take place during the first six months of 2023.

The history ofayahuascastretches back centuries throughout Central and South America, being used as a sacrament in ceremonies due to its powerful healing and visionary effects.

This sacred brew has also recently gained traction amongst the rich and famous. From Green Bay Packers quarterbackAaron Rodgers‘ countless manifestos towards psychedelics’ use, toWill Smith’s “surrendering” experience, ayahuasca has increased in popularity.

Creating a Consistent Experience

By creating an ayahuasca pill and standardizing dosing protocols, researchers hope to create a more consistent experience with predictable effects so they can study its therapeutic potential more accurately. If you have the goal of further researching areas such as post-traumatic stress disorder, depression and anxiety, a clinical trial is essential. Through this type of study it is possible to give participants precise doses over multiple weeks or months with follow up questionnaires and assessments to monitor progress over time. Creating an ayahuasca pill could make this kind of research possible.

Ayahuasca Pills Could Make Treatment More Accessible

Another benefit of creating an ayahuasca pill would be that it could make treatment more accessible for those who cannot travel to South America for traditional ceremonies or don’t have access to traditional healers who administer ayahuasca in other parts of the world. This could open up access to potential treatments for conditions like PTSD and depression for many more people around the world who may not otherwise have access to it.

Filament Healthis placing a bet on the natural products market for future psychedelic therapies, envisioning that certain individuals would choose to incorporate plant-based formulations instead of more pharmacological treatments when seeking “trips” with therapeutic benefits.

To support its efforts, Filament has entered into a partnership with UCSF and are already conducting psilocybin and psilocin clinical trials together.

With a large body ofresearchdemonstrating its potential therapeutic effects, ayahuasca has been identified as a possible treatment for an array of mental and physical illnesses such asdepression,suicidality,anxiety,trauma,grief,addictionandsubstance use disorderto evenneurodegenerative diseases.

As psychedelics become more of a commonplace discussion, and the manufacturing process for standardized ayahuasca is only just beginning, it appears to be the perfect time to explore this topic.

Exploring the Benefits of an Ayahuasca Pill

Why go through the effort of creating an ayahuasca pill when we can already make and take traditional hallucinogenic tea atretreatsin Brazil or Peru, as well as visit ayahuasca churches located around Canada and the USA? The answer lies in accessibility and consistency — two crucial elements that are essential for exploring this powerful medicine.

The Variability Issue

One of the major issues with administering ayahuasca in a traditional setting is that there is extreme variability in how much people receive. This can lead to drastically different experiences for different people within the same ceremony, which makes it difficult to measure the effects and benefits of ayahuasca usage. Benjamin Lightburn, Founder and CEO of Filament and connoisseur in pharmabotanica, spoke toBenzingaabout the details of plant extraction. He revealed that, “The amount of plants extracted, the different species used, and the strength of the extract… Different people in the same ceremony receive highly variable amounts of psychoactive substances.”



Source link

Continue Reading

Psychedelics

Lykos In Patent Mode On MDMA

Published

on

By


We don’t believe in taking out IP on MDMA

We don’t believe in taking out IP on MDMA

We don’t believe in taking out IP on MDMA

We don’t believe in taking out IP on MDMA

oh actually we do

 

 

Double Blind

In a shocking move that contradicts its previous stance on intellectual property, Lykos Therapeutics (formerly known as MAPS PBC) — the organization leading the movement to legalize MDMAassisted therapy — has filed multiple patent applications for specific forms and formulations of MDMA. Prior to this revelation, which was first reported on by Psychedelic Alpha, Lykos had long been praised in the psychedelic community and media for its “altruistic stance” in not seeking patent protections as part of its strategy, instead choosing to publish its research findings in scientific literature.

MAPS’s anti-patent stance, which intended to prevent MDMA from being monopolized, stood in stark contrast to the aggressive patent strategies of competitors like Compass Pathways and Atai Life Sciences. Rick Doblins, the founder of MAPS, had been analyzing the non-patentable status of MDMA since the late ‘80s, and in an article titled “MDMA Patentability and Orphan Drug Designation,” published in 1992, he wrote:

“It could be a major setback if MAPS funded MDMA research and secured approval for its medical use only to have someone else control it through an inexpensively obtained use patent.”

Read more

Lykos Therapeutics Quietly Moves to Patent MDMA

 



Source link

Continue Reading

Psychedelics

Press Release: PsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development Conference

Published

on

By


LOS ANGELES, May 17, 2024 (GLOBE NEWSWIRE) — PsychedelicNewsWire (“PNW”), a specialized communications platform for the psychedelics sector and one of the 60+ brands powered by IBN (“InvestorBrandNetwork”), is pleased to announce that it will be the Official Media Sponsor for the 4th Annual Psychedelic Therapeutics and Drug Development Conference (“the conference”), an industry flagship event dedicated to research and development of psychedelics in the healthcare space hosted by Arrowhead SciTech Conferences & Events (“Arrowhead”). The event will be held at the iconic Revere Hotel Boston Common, 200 Stuart Street, Boston, MA 02116 on 23-24 May 2024



Source link

Continue Reading

individualized treatment

Risks of Psychedelics for People with Personality Disorders

Published

on

By


While psychedelics have shown promise in treating certain mental health conditions, a recent study suggests they may pose risks for individuals with personality disorders. The findings underscore the importance of careful screening and personalized approaches in psychedelic-assisted therapy.

Navigating the Psychedelic Landscape: Potential Risks for Individuals with Personality Disorders

Psychedelics, including substances like psilocybin and LSD, have gained significant traction in recent years for their potential therapeutic benefits in treating mental health conditions such as depression, anxiety, and PTSD. However, a recent publication in the Journal of Psychopharmacology has raised concerns about the suitability of these substances for individuals with personality disorders.

The study surveyed individuals who had used psychedelics and who were also diagnosed with personality disorders. A considerable number of respondents reported negative and persistent psychological impacts following their psychedelic experiences. Notably, these included heightened anxiety, paranoia, mood instability, and an exacerbation of existing personality disorder symptoms.

Researchers suggest that the vulnerability of individuals with personality disorders to the adverse effects of psychedelics may stem from pre-existing challenges in emotional regulation, self-identity, and interpersonal relationships. The profound and introspective nature of psychedelic experiences can intensify these issues, potentially leading to psychological distress and symptom aggravation.

This research highlights the critical need for thorough screening and assessment in the context of psychedelic-assisted therapy. It suggests that individuals with personality disorders might require tailored therapeutic approaches and robust support systems to navigate potential risks and to secure safe and positive outcomes.

Why It Matters

The burgeoning interest in psychedelic therapy underscores the necessity to discern both the potential benefits and risks across different demographic groups. This study contributes valuable insights, particularly for clinicians and researchers, stressing the importance of personalized treatment plans and the cautious consideration of individual vulnerabilities when administering psychedelic-assisted therapy.

Potential Implications

The findings from this study emphasize the need for ethical and responsible practices within the field of psychedelic-assisted therapy. There is a pressing requirement for the development of detailed screening protocols that can identify individuals who may be more susceptible to the adverse effects of psychedelics. Furthermore, crafting specialized therapeutic strategies that cater specifically to the needs of individuals with personality disorders is essential for ensuring their safety and overall well-being during and after undergoing psychedelic experiences.

The Bigger Picture

The debate surrounding the therapeutic use of psychedelics is complex, with various factors influencing the suitability of these treatments for different individuals. While there are promising results in general populations, the nuanced needs and potential vulnerabilities of those with personality disorders require careful consideration to prevent harm and maximize therapeutic outcomes. This necessitates ongoing research, improved clinical protocols, and a commitment to patient-centered care in the burgeoning field of psychedelic medicine.

Source: Science Alert



Source link

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media